Mad in America

MARCH 15, 2025

This turn to ketamine is occurring despite the fact that the Food and Drug Administration has repeatedly warned that the FDA has not approved ketamine for the treatment of any psychiatric disorder (though controversially approving esketamine nasal spray). it felt like I was forever playing the arcade game of whack-a-mole.

Neurotransmitters and mental health 134

Neurotransmitters and mental health Trauma and the brain Manufacturing Pharmaceuticals 134

Bullet Psych

OCTOBER 7, 2022

Comorbidities : High incidence of lifetime mood disorder (usually MDD), anxiety disorders, substance use (particularly alcohol or stimulants), and personality disorders (most frequently borderline PD). The effective dose is typically higher than average depression treatment (60-80 mg/day). Other SSRIs (e.g.

Eating disorders 52

Eating disorders Dialectical Behavior Therapy Cognitive Behavioral Therapy Hospitality 52

Bullet Psych

JANUARY 22, 2023

Comorbidities : Like bulimia nervosa, in binge-eating disorder, there is an association between mood disorders , impulsivity, personality disorders (most commonly borderline PD ), anxiety disorders , and, to a lesser degree, substance use disorders. Other SSRIs (e.g.

Eating disorders 52

Eating disorders Dialectical Behavior Therapy Cognitive Behavioral Therapy Personality disorders 52

Mad in America

SEPTEMBER 18, 2024

The first NIMH treatment outcome study , which was published in 1989, found the drug treatment (imipramine) to be no more effective than placebo when measures were taken after three months of treatment. The NIH article also repeats another of STAR*D’s drug-related falsehoods.

Aging and mental health 145

Aging and mental health Cognitive Behavioral Therapy Manufacturing Anxiety disorders 145